Lung Giant Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Lung Giant Cell Carcinoma

MalaCards integrated aliases for Lung Giant Cell Carcinoma:

Name: Lung Giant Cell Carcinoma ¹¹ ¹⁴ ¹⁶

Carcinoma, Giant Cell ⁴³ ⁷¹

Giant Cell Carcinoma of Lung ⁷¹

Giant Cell Lung Carcinoma ¹¹

Giant Cell Carcinoma ¹¹

Carcinoma Giant Cell ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:5583

MeSH ⁴³ D018286

NCIt ⁴⁹ C3779 C4452

SNOMED-CT ⁶⁸ 254631008 42596004

EFO ¹⁶ EFO_1000332

UMLS ⁷¹ C0206703 C0345960

Sources

Summaries for Lung Giant Cell Carcinoma

Disease Ontology: ¹¹ A lung carcinoma that is located in large undifferentiated cells.

MalaCards based summary: Lung Giant Cell Carcinoma, also known as carcinoma, giant cell, is related to lung sarcomatoid carcinoma and epithelial-myoepithelial carcinoma, and has symptoms including fever, hemoptysis and dyspnea. An important gene associated with Lung Giant Cell Carcinoma is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Signal Transduction and Endometrial cancer. The drugs Nivolumab and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include large undifferentiated cells, lung and pancreas, and related phenotypes are Reduced mammosphere formation and Increased cell migration

Sources

Related Diseases for Lung Giant Cell Carcinoma

Diseases related to Lung Giant Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 446)

#	Related Disease	Score	Top Affiliating Genes
1	lung sarcomatoid carcinoma	30.3	NKX2-1 NAPSA KRT7 KRT5 KRAS EGFR
2	epithelial-myoepithelial carcinoma	30.2	KRT7 KRT5
3	angiosarcoma	30.1	VIM SERPINA3 KRAS
4	epithelioid sarcoma	30.0	VIM SERPINA3 KRT7
5	lung benign neoplasm	29.8	NKX2-1 KRT7 KRAS EGFR
6	malignant fibrous histiocytoma	29.8	VIM SERPINA3 CD68
7	small cell cancer of the lung	29.8	NKX2-1 MYC KRT7 EGFR
8	serous cystadenocarcinoma	29.8	NAPSA KRT7 KRAS
9	carcinosarcoma	29.7	VIM KRT7 KRAS EGFR
10	ovarian serous cystadenocarcinoma	29.7	SERPINA3 KRAS EGFR
11	endometrial adenocarcinoma	29.7	SERPINA3 KRT7 KRAS EGFR
12	mucoepidermoid carcinoma	29.7	VIM SERPINA3 KRT7 EGFR
13	squamous cell carcinoma	29.7	NKX2-1 MYC KRT7 KRAS EGFR
14	benign giant cell tumor	29.6	VIM SERPINA3 CD68
15	differentiated thyroid carcinoma	29.6	NKX2-1 KRAS ALK
16	liposarcoma	29.6	VIM MYC CD68
17	fibrous histiocytoma	29.5	VIM SERPINA3 CD68 ALK
18	lymphangitis	29.4	NKX2-1 KRT7 EGFR ALK
19	bronchiolo-alveolar adenocarcinoma	29.4	NKX2-1 KRT7 KRAS EGFR
20	breast ductal carcinoma	29.4	MYC KRT7 KRT5 EGFR
21	pancreatic cancer	29.4	VIM SERPINA3 MYC KRT7 KRAS IL6R
22	trachea carcinoma	29.3	NKX2-1 KRT7 KRT5 ALK
23	rhabdomyosarcoma	29.2	VIM MYC KRT7 KRAS EGFR ALK
24	endometrial cancer	29.2	MYC KRT7 KRAS GJA1 EGFR ALK
25	adenocarcinoma	29.1	NKX2-1 NAPSA KRT7 KRAS EGFR ALK
26	large cell carcinoma	28.9	NKX2-1 NAPSA KRT7 KRT5 KRAS EGFR
27	leukemia, acute myeloid	28.9	SERPINA3 MYC KRAS EGFR CXCL8 ALK
28	small cell carcinoma	28.9	NKX2-1 NAPSA KRT7 KRT5 EGFR ALK
29	pleomorphic carcinoma	28.6	NKX2-1 NAPSA KRT7 KRT5 KRAS EGFR
30	lung cancer susceptibility 3	28.6	NKX2-1 NAPSA MYC KRT7 KRAS EGFR
31	ovarian cancer	28.5	VIM MYC KRT7 KRAS IL6R GJA1
32	lung cancer	28.3	VIM SERPINA3 NKX2-1 NAPSA MYC KRT7
33	adenosquamous carcinoma	28.3	SERPINA3 NKX2-1 KRT7 KRT5 KRAS EGFR
34	large cell neuroendocrine carcinoma	28.3	NKX2-1 NAPSA KRT7 KRT5 KRAS EGFR
35	breast cancer	27.5	VIM SERPINA3 NKX2-1 MYC KRT7 KRT5
36	lung meningioma	10.3	VIM NKX2-1
37	epithelioid leiomyosarcoma	10.3	VIM SERPINA3
38	aspiration pneumonitis	10.3	SERPINA3 CXCL8
39	rare tumor	10.3
40	gallbladder signet ring cell adenocarcinoma	10.3	MYC KRT7
41	cervical mucinous adenocarcinoma	10.3	NAPSA KRT7
42	cervical clear cell adenocarcinoma	10.3	NAPSA KRT7
43	nephrogenic adenoma	10.3	NAPSA KRT7
44	ovarian endodermal sinus tumor	10.3	NAPSA KRT7
45	krukenberg carcinoma	10.3	NAPSA KRT7
46	urethral diverticulum	10.3	NAPSA KRT7
47	bronchus adenoma	10.3	NKX2-1 NAPSA
48	mucinous bronchioloalveolar adenocarcinoma	10.2	NKX2-1 KRT7
49	ovarian primitive germ cell tumor	10.2	NAPSA KRT7
50	ovarian mucinous adenocarcinoma	10.2	SERPINA3 KRT7

Graphical network of the top 20 diseases related to Lung Giant Cell Carcinoma:

Sources

Symptoms & Phenotypes for Lung Giant Cell Carcinoma

UMLS symptoms related to Lung Giant Cell Carcinoma:

fever; hemoptysis; dyspnea; coughing

GenomeRNAi Phenotypes related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.23	CXCL8 EGFR IL6R KRAS KRT7 MYC
2	Increased cell migration	GR00055-A-1	8.96	GJA1
3	Increased cell migration	GR00055-A-3	8.96	GJA1

MGI Mouse Phenotypes related to Lung Giant Cell Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.7	ALK EGFR IL6R KRAS MYC NKX2-1
2	normal	MP:0002873	9.56	ALK EGFR GJA1 IL6R KRAS MYC
3	no phenotypic analysis	MP:0003012	9.1	CD68 EGFR GJA1 KRAS MYC NKX2-1

Sources

Drugs & Therapeutics for Lung Giant Cell Carcinoma

Drugs for Lung Giant Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 7)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Nivolumab

Approved

Phase 2

946414-94-4

2

Ipilimumab

Approved

Phase 2

477202-00-9

3

Immunoglobulins

Phase 2

4

Immune Checkpoint Inhibitors

Phase 2

5

Antibodies, Monoclonal

Phase 2

6

Antibodies

Phase 2

7

Antineoplastic Agents, Immunological

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
2	Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma	Terminated	NCT00568906

Search NIH Clinical Center for Lung Giant Cell Carcinoma

Cochrane evidence based reviews: carcinoma, giant cell

Sources

Genetic Tests for Lung Giant Cell Carcinoma

Sources

Anatomical Context for Lung Giant Cell Carcinoma

Organs/tissues related to Lung Giant Cell Carcinoma:

FMA: Large Undifferentiated Cells

MalaCards : Lung, Pancreas, Thyroid, Prostate, Salivary Gland, Colon, Cervix

Sources

Publications for Lung Giant Cell Carcinoma

Articles related to Lung Giant Cell Carcinoma:

(show top 50) (show all 417)

#	Title	Authors	PMID	Year
1	[Expression of connexin 43 in lung cancer and its correlation with E-cadherin]. ⁵³ ⁶²	Zhang YX...Wang EH	16834907	2006
2	Effective asymmetry in gap junctional intercellular communication between populations of human normal lung fibroblasts and lung carcinoma cells. ⁵³ ⁶²	Zhang ZQ...Nicholson BJ	14656943	2004
3	Pleomorphic giant cell carcinoma of the esophagus with coexpression of cytokeratin and vimentin and neuroendocrine differentiation. ⁵³ ⁶²	Mosnier JF...Balique JG	10629146	2000
4	Effect of interleukin-6 on the growth of human lung cancer cell line. ⁵³ ⁶²	Fu J...Wu B	10374431	1998
5	[Differential expression and response of growth factors in metastatic variants of human pulmonary giant cell carcinoma cell line]. ⁵³ ⁶²	Zeng L...Fang W	10072879	1997
6	[Influence of transfection of sense- and antisense-TGF beta 1 gene on human pulmonary giant cell carcinoma cell proliferation]. ⁵³ ⁶²	Yang H...Shen H	10743067	1997
7	[Effects of metalloproteinases-1 (TIMP-1) cDNA transfection on biological behaviors of PG cells]. ⁵³ ⁶²	Zhou KX...Zheng J	7987710	1994
8	Immunohistochemical features of giant cell carcinoma of the lung: patterns of expression of cytokeratins, vimentin, and the mucinous glycoprotein recognized by monoclonal antibody A-80. ⁵³ ⁶²	Chejfec G...Gould VE	1710080	1991
9	Joining of the c-myc gene and a line 1 family member on chromosome 8 in a human primary giant cell carcinoma of the lung. ⁵³ ⁶²	Iizuka M...Sekiya T	2334929	1990
10	Pleomorphic giant cell carcinoma of the bladder: The diagnostic challenge of an unusual variant of urothelial carcinoma. ⁶²	Fernandez de Los Reyes I...Huarte Perez-Alfaro P	36257879	2022
11	Endometrial carcinoma with diffuse melanocytic differentiation: Clinicopathological and molecular analysis of a case with literature review and focus on differential diagnosis. ⁶²	Arciuolo D...Zannoni GF	36174440	2022
12	Endometrial giant cell carcinoma: new insights from a morphological, immunohistochemical, and molecular analysis of three cases. ⁶²	Arciuolo D...Zannoni GF	35305145	2022
13	Anaplastic thyroid carcinoma in a brush-tailed rock-wallaby (Petrogale penicillata). ⁶²	Doneley R...Suen WW	35257364	2022
14	The glottic-subglottic laryngectomy: Surgical technique, oncological, and functional outcomes. ⁶²	Bertolin A...Rizzotto G	34542917	2022
15	Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. ⁶²	Chang CL...Yu CJ	36324732	2022
16	[Long-term Survival Giant Cell Carcinoma of the Lung with Chest Wall Invasion by Multidisciplinary Therapy:Report of a Case]. ⁶²	Ishizumi T...Ikeda N	35249080	2022
17	Poorly Differentiated Cervical Squamous Cell Carcinoma Resembling Giant Cell Carcinoma of the Lung: Extreme Morphology of This Tumor and Its Clinical Course. ⁶²	Tohyama A...Yoshino K	36089344	2022
18	Pleomorphic (giant cell) carcinoma revisited: A historical perspective and conceptual reappraisal. ⁶²	Agaimy A	34583859	2021
19	Giant Cell Carcinoma of the Endometrium: A Case Report of a Rare Entity with Aggressive Behavior. ⁶²	Arafah M...Raddaoui E	34497258	2021
20	The importance of medical treatment before surgery in pleomorphic carcinoma of the lung: A case series study. ⁶²	Tormen F...Aramini B	34392016	2021
21	Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities. ⁶²	Ueberroth BE...Halfdanarson TR	34369897	2021
22	Successful treatment of metastatic bladder pleomorphic giant cell carcinoma with pembrolizumab. ⁶²	Nezu K...Ota S	34258526	2021
23	Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma. ⁶²	Agackiran Y...Aksu K	32929886	2021
24	Pleomorphic giant cell carcinoma of prostate: Rare tumor with unique clinicopathological, immunohistochemical, and molecular features. ⁶²	El-Zaatari ZM...Ro JY	33640702	2021
25	Low digestive hemorrhage due to giant-cell lung carcinoma metastasis. ⁶²	Ferrer-Inaebnit E...Gonzalez-Argente X	32988641	2021
26	Clinicopathological features and prognostic analysis of metastatic pulmonary sarcomatoid carcinoma: a SEER analysis. ⁶²	Xiao C...Liu L	33717562	2021
27	[Affinity chromatography based phosphoproteome research on lung cancer cells and its application]. ⁶²	Zhang B...Xiao H	34227361	2021
28	Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. ⁶²	Alhamar M...Williamson SR	32639612	2020
29	Extremely Aggressive Behavior of a Completely Resected Case of Gallbladder Undifferentiated Carcinoma, Giant Cell Type: a Rare Case with Breast, Neck Nodes, and Subcutaneous Scalp Nodules Metastasis. ⁶²	Anjali VR...Mallick S	31155696	2020
30	Gestational pulmonary giant cell carcinoma - An autopsy report. ⁶²	Shah R...Cochin T	31736471	2020
31	Pulmonary Sarcomatoid Giant Cell Carcinoma with Paraneoplastic Hypertrophic Osteoarthropathy: A Case Report. ⁶²	Igiebor O...McFarlane SI	32968695	2020
32	Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas diagnosed by endoscopic ultrasound guided biopsy. ⁶²	Speisky D...de Davila MTG	32863866	2020
33	[Pleomorphic giant cell carcinoma of the prostate: report of a case]. ⁶²	Wu YL...Duan GJ	31594053	2019
34	[A Case Of cT3bN2M0 Pleomorphic Giant Cell Carcinoma of the Bladder without Recurrence after Neoadjuvant Chemotherapy and Radical Cystectomy for 4 Years]. ⁶²	Kimura H...Fukuzawa S	31697880	2019
35	Giant cell carcinoma of the lung presenting as an isolated cyst containing air: A case report. ⁶²	Wang M...Tang Y	31096508	2019
36	Osteoclast-type giant cell carcinoma of the urinary bladder: An unusual and aggressive variant of urothelial carcinoma. ⁶²	Osman C...Fatih A	30581755	2019
37	Uterine giant cell carcinoma: a case report and review of the literature. ⁶²	Ayik Aydin H...Simsek T	31019844	2019
38	Osteoclast-like giant cell-rich carcinomas of the lung: a clinicopathological, immunohistochemical, and molecular study of 3 cases. ⁶²	Lindholm KE...Moran CA	30447297	2019
39	Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma. ⁶²	Baldovini C...Ciarrocchi A	31824199	2019
40	Pulmonary Sarcomatoid carcinoma: a surgical diagnosis and prognostic factors. ⁶²	Smadhi H...Megdiche ML	31535704	2019
41	Postmortem Investigation of Immunohistochemical Staining and Gross Description of Sarcomatoid Carcinoma of the Lung in a Patient With Extreme Leukemoid Reaction. ⁶²	Ammar A...Khan R	31272237	2019
42	A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review. ⁶²	Kakimoto T...Minematsu N	31737389	2019
43	Malignant Giant Cell Tumor of Soft Tissue: A Case Report of Intramuscular Malignant Giant Cell Carcinoma of the Tensor Fasciae Latae. ⁶²	Mensah D...Li ZY	31245324	2019
44	[Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma]. ⁶²	Liu L...Gao S	30591097	2018
45	HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder. ⁶²	Barresi V	29926185	2018
46	Letter to the editor: reply to Valeria Barresi "HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder". ⁶²	Varinot J...Comperat E	29934658	2018
47	Papillary thyroid carcinoma with pleomorphic tumor giant cells in a pregnant woman - a case report. ⁶²	Paulsson JO...Juhlin CC	29976183	2018
48	A rare case of giant cell lung carcinoma with intracardiac extension via the pulmonary vein and thrombus formation. ⁶²	Leivaditis V...Dougenis D	29977517	2018
49	Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma. ⁶²	Li Z...Cai J	30046230	2018
50	Combined small cell carcinoma with giant cell carcinoma component of the lung: A case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology. ⁶²	Ebisu Y...Tsuta K	29399198	2018

Sources

Genes for Lung Giant Cell Carcinoma

Genes related to Lung Giant Cell Carcinoma (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	20.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)
2	VIM	Vimentin	Protein Coding	11.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9391326 10629146 1710080
3	IL6R	Interleukin 6 Receptor	Protein Coding	11.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10374431
4	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	9.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	2334929
5	GJA1	Gap Junction Protein Alpha 1	Protein Coding	8.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14656943 16834907
6	SERPINA3	Serpin Family A Member 3	Protein Coding	7.18	DISEASES inferred ¹⁴ ¹⁴
7	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	6.37	DISEASES inferred ¹⁴
8	KRT7	Keratin 7	Protein Coding	6.23	DISEASES inferred ¹⁴
9	NKX2-1	NK2 Homeobox 1	Protein Coding	6.22	DISEASES inferred ¹⁴
10	SLC25A11	Solute Carrier Family 25 Member 11	Protein Coding	5.9	DISEASES inferred ¹⁴
11	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.73	DISEASES inferred ¹⁴
12	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	5.63	DISEASES inferred ¹⁴
13	KRT5	Keratin 5	Protein Coding	5.61	DISEASES inferred ¹⁴
14	CD68	CD68 Molecule	Protein Coding	5.58	DISEASES inferred ¹⁴
15	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	5.58	DISEASES inferred ¹⁴

Sources

Variations for Lung Giant Cell Carcinoma

Cosmic variations for Lung Giant Cell Carcinoma:

⁸ (show top 50) (show all 1546)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM86645186	RB1	lung,NS,carcinoma,giant cell carcinoma	c.245C>A	p.S82*	13:48307387-48307387	14
2	COSM150689102	RB1	lung,NS,carcinoma,giant cell carcinoma	c.245C>A	p.S82*	13:48307387-48307387	14
3	COSM111938756	EGFR	lung,NS,carcinoma,giant cell carcinoma	c.2438T>G	p.L813R	7:55191822-55191822	14
4	COSM111332419	EGFR	lung,NS,carcinoma,giant cell carcinoma	c.2438T>G	p.L813R	7:55191822-55191822	14
5	COSM147932132	EGFR	lung,NS,carcinoma,giant cell carcinoma	c.*563T>G	p.?	7:55191822-55191822	14
6	COSM86748127	EGFR	lung,NS,carcinoma,giant cell carcinoma	c.2573T>G	p.L858R	7:55191822-55191822	14
7	COSM102042323	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.-23-8009A>G	p.?	16:72958974-72958974	11
8	COSM87291734	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1172A>G	p.Q391R	16:72958974-72958974	11
9	COSM102040476	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.-23-8037G>T	p.?	16:72959002-72959002	11
10	COSM149314749	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1144G>T	p.G382C	16:72959002-72959002	11
11	COSM87290218	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1144G>T	p.G382C	16:72959002-72959002	11
12	COSM149318860	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1172A>G	p.Q391R	16:72958974-72958974	11
13	COSM126973051	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.770C>T	p.P257L	11:102229729-102229729	11
14	COSM145028029	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1154C>T	p.P385L	11:102229729-102229729	11
15	COSM128452039	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1142C>T	p.P381L	11:102229729-102229729	11
16	COSM85237448	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1304C>T	p.P435L	11:102229729-102229729	11
17	COSM143041512	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1316C>T	p.P439L	11:102229729-102229729	11
18	COSM127997731	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1256C>T	p.P419L	11:102229729-102229729	11
19	COSM133274224	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1268C>T	p.P423L	11:102229729-102229729	11
20	COSM90948266	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1202C>T	p.P401L	11:102229729-102229729	11
21	COSM108017622	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1009A>C	p.I337L	22:41653558-41653558	11
22	COSM95166535	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1159A>C	p.I387L	22:41653558-41653558	11
23	COSM97230831	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1159A>C	p.I387L	22:41653558-41653558	11
24	COSM105839764	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1009A>C	p.I337L	22:41653558-41653558	11
25	COSM106337415	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1159A>C	p.I387L	22:41653558-41653558	11
26	COSM103711109	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1036A>C	p.I346L	22:41653558-41653558	11
27	COSM85312404	XRCC1	lung,NS,carcinoma,undifferentiated carcinoma	c.1207A>G	p.M403V	19:43546970-43546970	11
28	COSM134125623	XRCC1	lung,NS,carcinoma,undifferentiated carcinoma	c.1114A>G	p.M372V	19:43546970-43546970	11
29	COSM100781761	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.724A>T	p.K242*	11:32392044-32392044	11
30	COSM111539040	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1309A>T	p.K437*	11:32392044-32392044	11
31	COSM149728755	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	11
32	COSM130518653	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.673A>T	p.K225*	11:32392044-32392044	11
33	COSM113475703	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	11
34	COSM111529696	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	11
35	COSM113484991	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	11
36	COSM147414475	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	11
37	COSM149739953	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	11
38	COSM148580942	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	11
39	COSM148593279	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	11
40	COSM91372655	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	11
41	COSM91383011	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	11
42	COSM147426277	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1309A>T	p.K437*	11:32392044-32392044	11
43	COSM124478343	WNT8A	lung,NS,carcinoma,undifferentiated carcinoma	c.422G>C	p.G141A	5:138088927-138088927	11
44	COSM104050903	WNT8A	lung,NS,carcinoma,undifferentiated carcinoma	c.368G>C	p.G123A	5:138088927-138088927	11
45	COSM105123686	WNT10B	lung,NS,carcinoma,undifferentiated carcinoma	c.*288A>C	p.?	12:48966259-48966259	11
46	COSM87652733	WNT10B	lung,NS,carcinoma,undifferentiated carcinoma	c.1006A>C	p.K336Q	12:48966259-48966259	11
47	COSM102763785	WNT10B	lung,NS,carcinoma,undifferentiated carcinoma	c.*288A>C	p.?	12:48966259-48966259	11
48	COSM99767946	USP5	lung,NS,carcinoma,undifferentiated carcinoma	c.755C>T	p.T252I	12:6856877-6856877	11
49	COSM84601598	USP5	lung,NS,carcinoma,undifferentiated carcinoma	c.755C>T	p.T252I	12:6856877-6856877	11
50	COSM121848752	USP38	lung,NS,carcinoma,undifferentiated carcinoma	c.994G>C	p.A332P	4:143197868-143197868	11

Sources

Expression for Lung Giant Cell Carcinoma

Search GEO for disease gene expression data for Lung Giant Cell Carcinoma.

Sources

Pathways for Lung Giant Cell Carcinoma

Pathways related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.51	VIM MYC KRAS IL6R GJA1 EGFR
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.49	MYC KRAS EGFR ALK
3	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.36	CXCL8 EGFR IL6R KRAS MYC
4	Cytoskeletal Signaling ³	12.3	VIM KRT7 KRT5 GJA1
5	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	11.96	MYC KRAS IL6R EGFR
6	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	11.85	VIM MYC GJA1
7	Colorectal Cancer Metastasis ⁶⁴	11.84	MYC KRAS IL6R EGFR
8	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.76	MYC KRAS EGFR
9	Gastrin signaling pathway ⁷⁴	11.61	MYC KRAS EGFR CXCL8
10	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.49	VIM MYC IL6R CXCL8
11	AP-1 transcription factor network ⁶¹	11.45	MYC GJA1 CXCL8
12	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.32	MYC IL6R CXCL8
13	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.18	MYC KRAS EGFR
14	Spinal cord injury ⁷⁴	11.08	VIM MYC GJA1 EGFR CXCL8
15	Syndecan-3-mediated signaling events ⁶¹	10.86	EGFR CXCL8
16	Bladder cancer ⁷⁴	10.86	MYC KRAS EGFR CXCL8
17	Mammary gland development pathway - Puberty (Stage 2 of 4) ⁷⁴	10.64	VIM MYC

Sources

GO Terms for Lung Giant Cell Carcinoma

Biological processes related to Lung Giant Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cerebral cortex cell migration	GO:0021795	9.46	NKX2-1 EGFR
2	intermediate filament organization	GO:0045109	9.43	VIM KRT7 KRT5
3	positive regulation of gene expression	GO:0010628	9.36	VIM NKX2-1 MYC KRAS GJA1 CXCL8

Sources

Sources for Lung Giant Cell Carcinoma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: LNG017 MIFTS: 50	Lung Giant Cell Carcinoma Categories: Cancer diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables